Skip to main content

Current status of chemoradiotherapy for gastric cancer in Japan

International Journal of Clinical Oncology volume 13, Article number: 117 (2008) Cite this article

Abstract

Chemoradiotherapy (CRT) is the latest modality to be explored as a treatment for gastric cancer. Advances have been made in the United States with CRT as preoperative or postoperative adjuvant treatment. The rationale for preoperative or postoperative adjuvant CRT is to increase the curability of surgery or to prevent local recurrence, because standard surgery (D0 or D1) is not sufficient to control local relapse and improve survival where disease has become advanced. D2 is standard in Japan and D2 gastrectomy plus postoperative adjuvant chemotherapy with S-1 is currently standard for stage II and III cancer. Predominant recurrence patterns associated with these advanced disease stages are peritoneal dissemination and hematogenous metastasis. Local relapse or regional nodal recurrence is infrequent. CRT has been provided at only a limited number of institutions in Japan. The response to and safety of CRT for gastric cancer, in combination with various chemotherapeutic agents, are currently being studied in patients with unresectable or recurrent disease. Considering the high response rate, CRT seems to be an attractive option. In the near future, an examination will be made to ascertain whether neoadjuvant CRT in combination with extensive surgery has survival benefits in the treatment of locally advanced disease. Prior to this, a phase I/II study should be conducted in patients with unresectable or recurrent disease.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Moertel CG, Childs DS Jr, Reitemeier RJ, et al. (1969) Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet II:865–867

    Article  Google Scholar 

  2. Schein P, Novak J (for GITSG) (1982) Combined modality therapy (XRT-chemo) versus chemotherapy alone for locally unresectable gastric cancer. Cancer Chemother Pharmacol 49:1771

    Google Scholar 

  3. Macdonald JS, Smalley SR, Benedetti J, et al. (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345:725–730

    PubMed  Article  CAS  Google Scholar 

  4. Ajani JA, Mansfield PF, Janjan N, et al. (2004) Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol 22:2774–2780

    PubMed  Article  CAS  Google Scholar 

  5. Ajani JA, Mansfield PF, Crane CH, et al. (2005) Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol 23:1237–1244

    PubMed  Article  CAS  Google Scholar 

  6. Ajani JA, Winter K, Okawara GS, et al. (2006) Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): Quality of combined modality therapy and pathologic response. J Clin Oncol 24:3953–3958

    PubMed  Article  CAS  Google Scholar 

  7. Ng K, Meyerhardt JA, Fuchs C (2007) Adjuvant and neoadjuvant approaches in gastric cancer. Cancer J 13:168–174

    PubMed  CAS  Article  Google Scholar 

  8. Abe M, Takahashi M, Ono K, et al. (1988) Japan gastric trials in intraoperative radiation therapy. Int J Radiat Oncol Biol Phys 15:1431–1433

    PubMed  CAS  Google Scholar 

  9. Saikawa Y, Kiyota T, Nakamura R, et al. (2006) A recent trial of chemo-radiation with S-1 against gastric cancer. Jpn J Cancer Chemother 33(Suppl I):99–105

    CAS  Google Scholar 

  10. Bonenkamp JJ, Hermans J, Sasako M, et al. (1999) Extended lymph-node dissection for gastric cancer. N Engl J Med 340:908–914

    PubMed  Article  CAS  Google Scholar 

  11. Wu C-W, Hsiung CA, Lo S-S, et al. (2006) Nodal dissection for patients with gastric cancer: a randomized controlled trial. Lancet Oncol 7:309–315

    PubMed  Article  CAS  Google Scholar 

  12. Sasako M, Sano T, Yamamoto A, et al. (2006) Randomized phase III trial of standard D2 versus D2 + para-aortic lymph node (PAN) dissection (D) for clinically M0 advanced gastric cancer: JCOG 9501. J Clin Oncol 24: 18S (abstract #LBA4015)

    Article  Google Scholar 

  13. Cunningham D, Allum WH, Stenning SP, et al. (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11–20

    PubMed  Article  CAS  Google Scholar 

  14. Sakuramoto S, Sasako M, Yamaguchi T, et al. (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357:1810–1820

    PubMed  Article  CAS  Google Scholar 

  15. Kim S, Lim DH, Lee J, et al. (2005) An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys 63:1279–1285

    PubMed  Article  Google Scholar 

  16. Boku N, Yamamoto S, Shirao K, et al. (2007) Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG 9912). J Clin Oncol 25:18S (abstract # LBA4513)

    Google Scholar 

  17. Narahara H, Koizumi W, Hara T, et al. (2007) Randomized phase III study of S-1 + cisplatin in the treatment for advanced gastric cancer (the SPRITS trial) SPRITS: S-1 + cisplatin vs S-1 in RCT in the treatment for stomach cancer. J Clin Oncol 25:18S (abstract #4514)

    Google Scholar 

Download references

Author information

Affiliations

  1. Department of Surgery, Osaka National Hospital, 2-1-14 Hoenzaka, Chuo-ku, Osaka, 540-0006, Japan

    Toshimasa Tsujinaka, Kazumasa Fujitani, Motohira Hirao & Yukimori Kurokawa

Authors
  1. Toshimasa Tsujinaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kazumasa Fujitani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Motohira Hirao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yukimori Kurokawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Toshimasa Tsujinaka.

About this article

Cite this article

Tsujinaka, T., Fujitani, K., Hirao, M. et al. Current status of chemoradiotherapy for gastric cancer in Japan. Int J Clin Oncol 13, 117 (2008). https://doi.org/10.1007/s10147-007-0743-1

Download citation

  • Received:

  • Published:

  • DOI: https://doi.org/10.1007/s10147-007-0743-1

Key words

  • Gastric cancer
  • Chemoradiotherapy
  • Adjuvant therapy
  • Unresectable/Recurrent cancer
  • Surgery
  • Lymphadenectomy